Vaccibody.com | Management
123
page-template-default,page,page-id-123,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive

Management

Martin Bonde BW (00000002)

Dr. Bonde has more than 25 years of international experience from the biotech industry.

Martin Bonde

Chief Executive Officer

Martin Bonde joined Vaccibody in August 2015. He holds a Ph.D. in Immunochemical Techniques and a Master of Science in Chemical Engineering from the Technical University of Denmark as well as a Bachelor of Commerce in International Economy from Copenhagen Business School.

 

Dr Bonde started his career in Dako AS, followed by Ostemeter AS (CEO), Torsana Biosensor AS (CEO), Celtor Biosystems Inc (EVP), Combio AS (CEO), Natimmune AS (CEO), Aros Pharma ApS (CEO) and most recently Epitherapeutics Aps now sold to Gilead (CEO).  His experience includes a significant number of transactions within business development, trade sales, mergers & acquisitions as well as management of research and development.

 

 

IMG_2802-3

Agnete B. Fredriksen, Chief Scientific Officer, Ph.D, is one of the inventors of the Vaccibody technology.

Agnete B. Fredriksen

Chief Scientific Officer

Agnete B. Fredriksen joined Vaccibody as Chief Scientific Officer in 2007. She holds a M.Sc., Ph.D.  from Institute of Immunology, University of Oslo, Rikshospitalet Medical Center, Oslo where she designed and developed the first Vaccibodies.

 

Previous employments include Researcher at Affitech AS, Oslo and Medinnova AS. Agnete is one of the inventors of the Vaccibody technology and received the King’s Gold Medal for her PhD thesis on Vaccibodies.

Mads crop BW updated dimensions

Mads B. Axelsen, MD, has extensive international experience in both biotech and large pharma.

Mads B. Axelsen

Chief Medical Officer

Mads Buhl Axelsen joined Vaccibody in June 2017. He holds a MD from Medical School, University of Copenhagen, an ECPM: a 2 year postgraduate educational program in pharmaceutical medicine, and a Master of Medical Business Strategies from Copenhagen Business School.

 

Mads has since 1990 worked in drug development with medical aspects of clinical research regulatory affairs in varies large pharma and biotech companies. Mads started his career in Leo Pharma followed by Novo Nordisk A/S in DK, Novo Nordisk Pharmaceutical Inc., Princeton, USA; NatImmune A/S, Neurokey A/S, Hemofocus Aps., most recently Mads worked as an International Medical Director at Novo Nordisk A/S.